PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
Status:
Completed
Trial end date:
2018-08-22
Target enrollment:
Participant gender:
Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It is a
multi-center, nonrandomized, open label, phase II investigation of PNT2258 to characterize
anti-tumor activity and collect safety data on patients with relapsed or refractory (r/r)
diffuse large B-cell lymphoma.